Effect of sodium-dependent glucose transporter inhibitors on glycated hemoglobin A1c after 24 weeks in patients with diabetes mellitus

Chen, Mao-Bing; Wang, Hua; Zheng, Qi-Han; Xu, Hualan; Cui, Wei-Yan

doi:10.1097/md.0000000000024101

Cited by 3 publications

(1 citation statement)

References 52 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sodium-glucose co-transporter-2 (SGLT-2) inhibitors yield significant contribution to the treatment of the patients with T2DM. A recent meta-analysis concluded that this group of anti-diabetic drugs significantly reduced glycated hemoglobin (HbA1c) levels in the diabetic population [1]. Besides its potent activity in decreasing HbA1c and contribution to the better metabolic control in T2DM, SGLT-2 inhibitors also decrease pulmonary artery pressure in diabetic subjects suffer from heart failure [2].…”

Section: Introductionmentioning

confidence: 99%

Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study

et al. 2021

View full text Add to dashboard Buy / Rent full text

Background Empagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, yielded significant beneficiaries in the treatment of type 2 diabetes mellitus (T2DM). It is particularly benefited the diabetic subjects with heart conditions. Aims We aimed to obtain a real-world data about the effects of empagliflozin add-on treatment on metabolic parameters, cardiovascular risk factors, and anthropometric measures in patients with T2DM. Methods Type 2 diabetic patients with established coronary heart disease whom empagliflozin added to their treatment were enrolled in the study. Anthropometric measures, clinical and laboratory data, were obtained before and at the 6th month of the empagliflozin treatment. All data before and at the 6th month were compared. Results Body weight (p < 0.001), body mass index (p < 0.001), waist (p < 0.001) and hip (p < 0.001) circumferences, systolic blood pressure (p = 0.006), heart rate (p = 0.01), LDL cholesterol (p = 0.01), fasting plasma glucose (p < 0.001), and HbA1c (p < 0.001) levels were significantly reduced on 6th month of empagliflozin treatment compared to the baseline values. Estimated GFR (p = 0.66), serum creatinine (p = 0.8), uric acid (p = 0.40), total cholesterol (p = 0.053), triglyceride (p = 0.057), and HDL (p = 0.09) levels were not significantly changed. Conclusions We suggest that empagliflozin treatment may improve anthropometric measures, metabolic parameters, and blood pressure and does not cause deterioration in kidney functions in type 2 diabetic patients with established coronary heart disease.

show abstract

Section: Introductionmentioning

confidence: 99%